COPD - Nationale VersorgungsLeitlinien

50. Nolan D,White P. FEV1 and PEF in COPD management. Thorax 1999;54(5):468-9.
51. Burrows B. The course and prognosis of different types of chronic airflow limitation in a general
population sample from Arizona: comparison with the Chicago "COPD" series. Am Rev Respir Dis
1989;140(3 Pt 2):S92-S94.
52. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A
15-year follow-up study. Am Rev Respir Dis 1979;119(6):895-902.
53. Tweeddale PM, Alexander F, McHardy GJ. Short term variability in FEV1 and bronchodilator
responsiveness in patients with obstructive ventilatory defects. Thorax 1987;42(7):487-90.
54. Quanjer PH. Standardised lung function testing. Official statement of the European Respiratory
Society. Eur Respir J 1993;6 Suppl 16:5-40.
55. Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response to
bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern
Med 1988;148(9):1949-52.
56. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhouse MT.
Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and
quality of life. Am Rev Respir Dis 1987;135(5):1069-74.
57. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterolipratropium
combination (Dey combination) is superior to either agent alone in the treatment of
chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration
1998;65(5):354-62.
58. Berger R,Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable
"fixed" airway obstruction. Am Rev Respir Dis 1988;138(3):624-9.
59. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic
obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991;114(3):216-23.
60. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive
pulmonary disease. 2004 [cited: 2005 May 30]. Available from:
http://www.thoracic.org/copd/copdpdf.asp
61. Roberts CM, Bugler JR, Melchor R, Hetzel MR, Spiro SG. Value of pulse oximetry in screening for
long-term oxygen therapy requirement. Eur Respir J 1993;6(4):559-62.
62. Hughes JM,Pride NB. In defence of the carbon monoxide transfer coefficient Kco (TL/VA). Eur
Respir J 2001;17(2):168-74.
63. Gould GA, Redpath AT, Ryan M, Warren PM, Best JJ, Flenley DC, MacNee W. Lung CT density
correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J
1991;4(2):141-6.
64. Gevenois PA, De Maertelaer V, De Vuyst P, Zanen J, Yernault JC. Comparison of computed density
and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med
1995;152(2):653-7.
65. McLean A, Warren PM, Gillooly M, MacNee W, Lamb D. Microscopic and macroscopic
measurements of emphysema: relation to carbon monoxide gas transfer. Thorax 1992;47(3):144-9.
66. Worth H, Breuer HW, Dorow P. Empfehlungen zur Durchführung und Bewertung von
Belastungsuntersuchungen in der Pneumologie. Deutsche Gesellschaft für Pneumologie.
Pneumologie 1998;52:225-31.
67. Morgan MD, Denison DM, Strickland B. Value of computed tomography for selecting patients with
bullous lung disease for surgery. Thorax 1986;41(11):855-62.
© 2006
82